Medicines Australia


On 27 March 2020, Medicines Australia (MA) lodged an application for authorisation on behalf of itself and its members, and the Generic and Biosimilar Medicines Association (GBMA) and its members (together the MA/GBMA Working Group) and any future members of the MA/GBMA Working Group. MA initially sought authorisation for six months to implement a coordinated strategy in relation to the supply of essential medicines and related supplies in response to the current COVID-19 pandemic. MA also sought urgent interim authorisation, in light of the current demands on the health system and in order to assist relevant government bodies.

On 3 April 2020, the ACCC granted interim authorisation with certain conditions.

On 26 June 2020, the ACCC issued a draft determination proposing to grant authorisation with certain conditions until 27 March 2021. In its submission on the draft determination, MA requested authorisation for 12 months.

On 24 September 2020, the ACCC issued a final determination granting authorisation to MA with certain conditions until 30 September 2021. A copy of the final determination is available below.

A timetable is set out below for your information

Indicative date

Stage in assessment process

27 March 2020

Lodgement of application, including request for interim authorisation

3 April 2020

ACCC decision on interim authorisation

6 April 2020

Public consultation

27 April 2020

Closing date for submissions

18 May 2020

Applicant responds to issues raised in public consultation process

26 June 2020

ACCC draft determination

July/August 2020

Public consultation on the draft determination

24 September 2020

ACCC final determination


  • Medicines Australia

Authorisation number(s)

  • AA1000486-1



Document title Date

Submissions - after draft decision

Document title Date